Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed(A Prospective Non-controlled Single Arm Trial)

NCT06972602 is registered in ClinicalTrials.gov with Eye & ENT Hospital of Fudan University as lead sponsor.

NCT NCT06972602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06972602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed(A Prospective Non-controlled Single Arm Trial)
Lead sponsor
Eye & ENT Hospital of Fudan University
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinoblastoma, retinoblastoma, recurrent